Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Ziconotide for Neuropathic Pain in Cancer
NCT00996983Phase 2Unknown
- Sponsor
- National Cancer Institute
- Start
- Sep 2009
- Primary completion
- Dec 2024
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ziconotide in neuropathic pain, sponsored by National Cancer Institute. Primary endpoint: Response rate (> 30% reduction in VASPI). Status: unknown.
02
Drugs
ziconotide
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT00996983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00996983.